DailyMed Update Clarifies Bismuth Subsalicylate Use, Risks, and Dose Limits

DailyMed’s latest label for bismuth subsalicylate places a familiar OTC agent under a sharper clinical lens. The product, marketed as STOMACH RELIEF REGULAR STRENGTH, is a 525 mg/30 mL oral suspension used as an upset stomach reliever and antidiarrheal. Its labeled uses span travelers’ diarrhea, diarrhea, and upset stomach tied to overindulgence in food and drink, including heartburn, indigestion, nausea, gas, and belching. The formulation is positioned as a low-sodium, sugar-free liquid for short-term symptom control rather than ongoing gastrointestinal disease management.

The label update is clinically useful because it makes the product’s benefits and boundaries explicit. Bismuth subsalicylate works through more than one pathway: it exerts antisecretory and anti-inflammatory effects in the gut while also binding toxins and supporting stool normalization. In practice, that broad activity is what makes it useful for the kind of acute, mixed-symptom presentations that fill urgent care clinics, travel medicine advice lines, and household medicine cabinets. The same salicylate core that contributes to efficacy also drives the most important cautions.

A single 30 mL dose contains 525 mg of bismuth subsalicylate and 260 mg of salicylate. Each dose also contributes 14 mg of potassium and 10 mg of sodium, a detail that matters for patients tracking electrolytes or managing fluid and salt intake. The liquid is described as pink, viscous, and wintergreen-flavored, with a safety-sealed bottle containing 236 mL. Those product characteristics are mundane on paper, but they affect adherence in real life, especially when patients are already nauseated and are trying to measure repeated doses accurately.

Salicylate Exposure Drives the Most Important Safety Warnings

The strongest warning on the label concerns Reye’s syndrome. Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. The label also instructs families to seek medical attention if behavioral changes with nausea and vomiting occur, since those symptoms can be an early sign of this rare but serious illness. This is a standard salicylate-related precaution, but it remains easy to miss in home treatment of febrile viral syndromes where gastrointestinal symptoms overlap with the underlying illness.

The allergy alert is equally direct: the product contains salicylate and should not be taken by people allergic to salicylates, including aspirin, or by those already taking other salicylate products. The contraindications extend to patients with an ulcer, a bleeding problem, or bloody or black stool. Those restrictions follow basic pharmacology. Any salicylate-containing agent can worsen mucosal bleeding risk, and the presence of melena or hematochezia should shift attention away from self-treatment and toward evaluation for gastrointestinal hemorrhage or another serious cause.

The label also advises a clinician’s input before use in patients with fever or mucus in the stool. Fever and inflammatory stool features can suggest invasive infection, dysentery, or another process where simple symptomatic suppression is the wrong first move. Before use, patients taking anticoagulation therapy, or those with diabetes, gout, or arthritis, are also told to ask a doctor or pharmacist. Those prompts matter because this over-the-counter medicine does not exist outside the rest of a patient’s medication list; salicylate exposure can complicate antithrombotic care, and the symptom profile may overlap with conditions already being treated pharmacologically.

A temporary darkening of the stool or tongue can occur and is described as harmless. In outpatient practice, that reassurance is important because the color change can alarm patients who are not expecting it, especially when they are already monitoring for black stool from gastrointestinal bleeding. One sentence separates a benign drug effect from a potentially serious adverse sign, and the label does not leave room for ambiguity.

Short Courses Only, with Clear Stop Points

The dosing instructions are intentionally narrow. Adults and children 12 years and over may take 30 mL every half hour or 60 mL every hour as needed for diarrhea or travelers’ diarrhea. For upset stomach, heartburn, indigestion, and nausea related to overindulgence, the adult and adolescent dose is 30 mL every half hour as needed. Use should not exceed 8 doses, or 240 mL, in 24 hours. For diarrhea, the product should be used until the symptom stops, but not for more than 2 days. Children under 12 years are told to ask a doctor.

That stop point is clinically important. Acute diarrhea often settles with hydration and time, but persistent symptoms can signal infection, inflammatory bowel disease, medication toxicity, or another diagnosis that needs evaluation rather than repeated self-dosing. The label reinforces that message by advising patients to drink plenty of clear fluids to help prevent dehydration caused by diarrhea. In other words, the medication is adjunctive; fluid replacement remains the foundation of care.

The label also gives an explicit threshold for escalation: symptoms that worsen or last more than 2 days, ringing in the ears, or loss of hearing warrant medical review. Tinnitus and hearing changes fit with salicylate toxicity, which makes that warning pharmacologically coherent. The combination of antidiarrheal use and salicylate exposure can look safe on the shelf but become clinically relevant if dosing drifts upward or symptoms are misread as benign when they are not.

Labeling Details Reinforce OTC Boundaries and Storage Discipline

The product is labeled as an OTC monograph drug and was updated on November 11, 2026, with a marketing start date of October 21, 2024. It is listed under NDC 70000-0698-1 and distributed by Cardinal Health 110, LLC. The bottle should be stored at room temperature, protected from freezing, and kept away from excessive heat above 104°F or 40°C. Those instructions may seem routine, but suspension quality can change if storage conditions are ignored, and patients frequently keep this kind of medicine in cars, bathrooms, or kitchen cabinets where temperature swings are common.

Inactive ingredients include carboxymethylcellulose sodium, D&C Red No. 22, D&C Red No. 28, microcrystalline cellulose, potassium hydroxide, potassium sorbate, purified water, salicylic acid, dimethicone emulsion, sodium benzoate, sucralose, xanthan gum, and gellan gum. The formulation is therefore not just a single active ingredient in water; it is a stabilized suspension built for oral dosing consistency and palatability. The label also notes a safety seal and instructs consumers not to use the product if the shrink band is missing or broken.

Breast-feeding and pregnancy require professional input before use. The label does not extend beyond that caution, and it does not provide a broader risk-benefit discussion. For a common OTC product, that restraint is appropriate. The main clinical message remains focused: bismuth subsalicylate can be useful for short-term symptom relief, but salicylate-related risks, pediatric restrictions, bleeding concerns, and persistence beyond 48 hours all deserve the same level of attention as the symptom relief itself.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by DailyMed Drug Label Updates.